Axovant Sciences Inc   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: London United Kingdom (2014)

Organization Overview

First Clinical Trial
2015
NCT02585934
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Axovant Sciences | Axovant Sciences, Inc. | Axovant Sciences, Inc., Clinical Research | Axovant Sciences Inc., Senior Vice President, Clinical Research | Axovant Sciences, Inc., Senior VP Clinical Research | Axovant Sciences, Inc., Vice President, Clinical Research | Axovant Sciences Ltd. | Sio Gene Therapies

Active Ingredients

Drugs in Phase 3 Trials (1)

intepirdine (5 trials)

Drugs in Phase 2 Trials (3)

aav9-glb1 (1 trial)

nelotanserin (3 trials)

oxb-102 (1 trial)

Drugs in Phase 1 Trials (1)

axo-aav-gm2 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Dementia (Phase 3)

Disease (Phase 2)

Gangliosidoses (Phase 2)

Gangliosidosis, GM1 (Phase 2)

Hallucinations (Phase 2)

Lewy Body Disease (Phase 3)

Mental Disorders (Phase 2)

Parkinson Disease (Phase 2)

REM Sleep Behavior Disorder (Phase 2)

Sandhoff Disease (Phase 1)

Tay-Sachs Disease (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 5